Kezar Life Sciences Inc

Company Profile

Kezar Life Sciences Inc had its IPO on 2018-06-21 under the ticker symbol KZR.

The company operates in the Healthcare sector and Biotechnology industry. Kezar Life Sciences Inc has a staff strength of 84 employees.

Stock update

Shares of Kezar Life Sciences Inc opened at $1.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.18 - $1.25, and closed at $1.22.

This is a +1.67% increase from the previous day's closing price.

A total volume of 167,029 shares were traded at the close of the day’s session.

In the last one week, shares of Kezar Life Sciences Inc have slipped by -22.29%.

Kezar Life Sciences Inc's Key Ratios

Kezar Life Sciences Inc has a market cap of $114.13 million, indicating a price to book ratio of 1.6878 and a price to sales ratio of 0.

In the last 12-months Kezar Life Sciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-89586000. The EBITDA ratio measures Kezar Life Sciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kezar Life Sciences Inc’s operating margin was 0% while its return on assets stood at -19.42% with a return of equity of -31.17%.

In Q2, Kezar Life Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Kezar Life Sciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kezar Life Sciences Inc’s profitability.

Kezar Life Sciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.2622. Its price to sales ratio in the trailing 12-months stood at 0.

Kezar Life Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$263.38 million

Total Liabilities

$13.74 million

Operating Cash Flow

$0

Capital Expenditure

$1.38 million

Dividend Payout Ratio

0%

Kezar Life Sciences Inc ended 2024 with $263.38 million in total assets and $0 in total liabilities. Its intangible assets were valued at $263.38 million while shareholder equity stood at $232.28 million.

Kezar Life Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $13.74 million in other current liabilities, 73000.00 in common stock, $-295400000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.11 million and cash and short-term investments were $236.59 million. The company’s total short-term debt was $2,782,000 while long-term debt stood at $9.95 million.

Kezar Life Sciences Inc’s total current assets stands at $243.50 million while long-term investments were $0 and short-term investments were $208.48 million. Its net receivables were $0 compared to accounts payable of $2.49 million and inventory worth $0.

In 2024, Kezar Life Sciences Inc's operating cash flow was $0 while its capital expenditure stood at $1.38 million.

Comparatively, Kezar Life Sciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.22

52-Week High

$10.51

52-Week Low

$1.17

Analyst Target Price

$13

Kezar Life Sciences Inc stock is currently trading at $1.22 per share. It touched a 52-week high of $10.51 and a 52-week low of $10.51. Analysts tracking the stock have a 12-month average target price of $13.

Its 50-day moving average was $1.93 and 200-day moving average was $4.01 The short ratio stood at 6.59 indicating a short percent outstanding of 0%.

Around 1862.7% of the company’s stock are held by insiders while 8668.6% are held by institutions.